Indevus completes enrollment in pharmacokinetic trial for its testosterone preparation Nebido

By Lisa Kerner

Charlotte, N.C., June 22 - Indevus Pharmaceuticals, Inc. said it has completed the enrollment of patients for its pharmacokinetic trial for Nebido, a long-acting injectable testosterone preparation for the treatment of male hypogonadism.

In the trial, hypogonadal men will receive Nebido by intramuscular injection every 12 weeks.

The primary endpoint is the assessment of average serum testosterone levels measured after the fourth injection, according to a company news release.

Nebido was recently approved and launched in Europe. Indevus acquired U.S. rights to the product from Schering AG, Germany.

Located in Lexington, Mass., Indevus acquires, develops and commercializes of products for urology, gynecology and men's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.